I am pleased to share with you the 2018 Cancer Trials Australia Annual Report.

Download the 2018 Annual Report Here.

The 2018 calendar year saw growth in both CTA service provision and membership, welcoming Epworth Healthcare, Calvary Central Districts Hospital and Murdoch Children’s Research Institute, and more recently, Coffs Harbour Health Campus.

Building on the back of growth in 2016 and 2017, almost all CTA service metrics improved further in 2018; feasibilities grew 5%, oncology submissions increased 16%, and the number of patients accrued to CTA supported trials increased by over 10%. Significant expansion occurred in non-oncology submissions with growth of 150%. The CTA Finance team issued in excess of 4,400 invoices on behalf of our Members, and more than $23M was distributed to CTA Members, up 22% on the previous year.

Celebrating International Clinical Trials Day in May 2018, CTA marked an important milestone in our support of 1000 commercially sponsored trials; an outstanding achievement for both CTA and our Members.

Our key programs in 2018 included (i) strategic investment in our information management systems, (ii) winning a tender with the Victorian Comprehensive Cancer Centre to provide site management services for the VCCC’s Investigator Initiated Trial Program, (iii) ensuring a more prominent role in both national and international forums, (iv) further enhancing linkages across metro and regional hospitals and (v) significant expansion of trial support in non-oncology therapeutic areas.

Cancer Trials Australia is better positioned than ever to continue to support clinical trial activity across our growing membership, helping to ensure Australia remains a destination of choice for clinical trials and securing earlier access to novel therapies for Australian patients. I would like to take the opportunity to thank all CTA staff, as well as our network Member personnel, for all the hard work they undertake that is essential to enable the CTA network to flourish.

For a hard copy of the report please contact [email protected]

Kurt Lackovic
Chief Executive Officer